Last reviewed · How we verify
YESAFILI (AFLIBERCEPT-JBVF)
YESAFILI (generic name: AFLIBERCEPT-JBVF) is a drug developed by BIOCON BIOLOGICS INC. It is currently FDA-approved.
YESAFILI is a vascular endothelial growth factor A inhibitor, a protein-based drug that targets VEGF-A. It is used to treat conditions such as Age-Related Macular Degeneration, specifically Exudative Age-Related Macular Degeneration, by inhibiting the action of VEGF-A.
At a glance
| Generic name | AFLIBERCEPT-JBVF |
|---|---|
| Sponsor | BIOCON BIOLOGICS INC |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YESAFILI CI brief — competitive landscape report
- YESAFILI updates RSS · CI watch RSS
- BIOCON BIOLOGICS INC portfolio CI
Frequently asked questions about YESAFILI
What is YESAFILI?
Who makes YESAFILI?
What is the generic name of YESAFILI?
What development phase is YESAFILI in?
Related
- Manufacturer: BIOCON BIOLOGICS INC — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing